A. Seckinger

发表

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.

D. Hose, H. Goldschmidt, A. Jauch, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transplantation of mesenchymal stromal cells on mineralized collagen leads to ectopic matrix synthesis in vivo independently from prior in vitro differentiation.

P. Kasten, A. Seckinger, N. Südkamp, 2006, Cytotherapy.

Evaluation of Mineralized Collagen and α-Tricalcium Phosphate as Scaffolds for Tissue Engineering of Bone Using Human Mesenchymal Stem Cells

P. Kasten, A. Ho, A. Seckinger, 2004, Cells Tissues Organs.

Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma

B. Klein, D. Hose, A. Seckinger, 2015, Journal of Hematology & Oncology.

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial

J. Moreaux, D. Hose, H. Goldschmidt, 2019, Journal of Hematology & Oncology.

Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone

D. Hose, H. Goldschmidt, A. Jauch, 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Dose-dependent effects of intravenous allogeneic mesenchymal stem cells in the infarcted porcine heart.

H. Katus, A. Seckinger, H. Kuecherer, 2009, Stem cells and development.

Stem cell therapy improves myocardial perfusion and cardiac synchronicity: new application for echocardiography.

H. Katus, A. Seckinger, U. Krause, 2007, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

Dendritic Glycopolymer as Drug Delivery System for Proteasome Inhibitor Bortezomib in a Calcium Phosphate Bone Cement: First Steps Toward a Local Therapy of Osteolytic Bone Lesions.

D. Hose, M. Gelinsky, Martin Müller, 2015, Macromolecular bioscience.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

D. Hose, H. Goldschmidt, A. Jauch, 2018, Blood advances.

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells

D. Hose, H. Goldschmidt, G. Morgan, 2015, BMC Medical Genomics.

Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma

D. Hose, A. Seckinger, G. Cowan, 2015, Oncotarget.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma

B. Klein, D. Hose, C. Bokemeyer, 2014, Leukemia.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

D. Hose, H. Goldschmidt, A. Jauch, 2016, Haematologica.

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma

M. Beksac, D. Hose, F. Zhan, 2021, Molecular Cancer.

Identification of patients with smouldering multiple myeloma at ultra‐high risk of progression using serum parameters: the Czech Myeloma Group model

D. Hose, H. Goldschmidt, S. Ševčíková, 2020, British journal of haematology.

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.

C. Klein, D. Hose, F. Prósper, 2017, Cancer cell.

Target Expression , Genera tion , Preclinical Activity , and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM 801 for Multiple Myeloma Treatment Graphical

C. Klein, D. Hose, F. Prósper, 2022 .

CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment

S. Haferkamp, M. Boutros, D. Hose, 2020, Cancer Immunology Research.

Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6.

T. Rème, J. Rossi, B. Klein, 2013, Blood.

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome

D. Hose, H. Goldschmidt, F. Zhan, 2018, Blood Cancer Journal.

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial

D. Hose, H. Goldschmidt, A. Ho, 2016, Oncotarget.

RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma

D. Hose, F. Zhan, A. Seckinger, 2020, Leukemia.

Induction of angiogenesis by normal and malignant plasma cells.

T. Rème, J. Rossi, B. Klein, 2009, Blood.

Intravenous delivery of autologous mesenchymal stem cells limits infarct size and improves left ventricular function in the infarcted porcine heart.

A. Ho, H. Katus, A. Seckinger, 2007, Stem cells and development.

Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines

A. Seckinger, J. Burhenne, S. Dettmer, 2016, Naunyn-Schmiedeberg's Archives of Pharmacology.

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells

G. Requirand, T. Rème, B. Klein, 2018, British Journal of Cancer.

Quantification of plasma cell dynamics using mathematical modelling

D. Hose, A. Marciniak-Czochra, A. Seckinger, 2018, Royal Society Open Science.

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma

B. Klein, J. Moreaux, D. Hose, 2014, Oncotarget.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

D. Hose, H. Goldschmidt, A. Jauch, 2018, Blood advances.

Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient

A. Seckinger, J. Burhenne, Dirk Theile, 2017, Cancer Chemotherapy and Pharmacology.

Comparison of immunological properties of bone marrow stromal cells and adipose tissue-derived stem cells before and after osteogenic differentiation in vitro.

P. Kasten, A. Seckinger, N. Südkamp, 2007, Tissue engineering.

miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression

J. Zimmermann, V. Beneš, B. Klein, 2015, Oncotarget.

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance

D. Hose, A. Jauch, A. Ho, 2018, Front. Immunol..

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma

G. Requirand, B. Klein, J. Moreaux, 2017, Oncotarget.

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma

D. Hose, H. Goldschmidt, F. Bassermann, 2021, Blood advances.

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2019, Leukemia.

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance

D. Hose, H. Goldschmidt, A. Jauch, 2018, Leukemia.

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

Axel Benner, John D. Shaughnessy, Thomas Hielscher, 2011, Haematologica.

BMP‐6 Loaded Polyelectrolyte Complex Nanoparticles Inducing Osteogenic Differentiation and Apoptosis of Malignant Plasma Cells for Local Treatment of Multiple Myeloma

D. Hose, E. A. Cavalcanti-Adam, A. Seckinger, 2021, Particle & Particle Systems Characterization.

BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma

G. Requirand, B. Klein, J. Moreaux, 2018, Cytometry. Part B, Clinical cytometry.

Drug Release as a function of bioactivity, incubation regime, liquid, and initial load: Release of bortezomib from calcium phosphate-containing silica/collagen xerogels.

D. Hose, R. Schnettler, A. Seckinger, 2018, Journal of biomedical materials research. Part B, Applied biomaterials.

RNA-Sequencing from Low-Input Material in Multiple Myeloma for Application in Clinical Routine.

V. Beneš, D. Hose, A. Seckinger, 2018, Methods in molecular biology.

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1

B. Klein, D. Hose, H. Goldschmidt, 2014, Oncotarget.

The Glycome of Normal and Malignant Plasma Cells

B. Klein, J. Moreaux, D. Hose, 2013, PloS one.

Clinical and prognostic role of annexin A2 in multiple myeloma.

T. Rème, B. Klein, J. Moreaux, 2012, Blood.

Clinical and prognostic role of annexin A 2 in multiple myeloma

T. Rème, B. Klein, J. Moreaux, 2012 .

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis

J. D. Vos, V. Pantesco, B. Klein, 2009, Oncogene.

Gene Expression Profiling in Multiple Myeloma—Reporting of Entities, Risk, and Targets in Clinical Routine

Thomas Hielscher, Hartmut Goldschmidt, Dirk Hose, 2011, Clinical Cancer Research.

Primitive and committed human hematopoietic progenitor cells interact with primary murine neural cells and are induced to undergo self-renewing cell divisions.

A. Ho, A. Seckinger, R. Saffrich, 2007, Experimental hematology.

Copresentation of BMP-6 and RGD Ligands Enhances Cell Adhesion and BMP-Mediated Signaling

D. Hose, S. Vukicevic, E. A. Cavalcanti-Adam, 2019, Cells.

The Many Facets of SDF-1α, CXCR4 Agonists and Antagonists on Hematopoietic Progenitor Cells

A. Ho, D. Wong, C. Roderburg, 2007, Journal of biomedicine & biotechnology.

Human Mesenchymal Stromal Cells Regulate Initial Self‐Renewing Divisions of Hematopoietic Progenitor Cells by a β1‐Integrin‐Dependent Mechanism

A. Ho, A. Seckinger, R. Saffrich, 2007, Stem cells.

Quantitative Efficacy and Fate of Mesenchymal Stromal Cells Targeted to Cardiac Sites by Radiofrequency Catheter Ablation

H. Katus, A. Seckinger, Dierk Thomas, 2020, Cell transplantation.

Regenerative capacity of intravenous autologous, allogeneic and human mesenchymal stem cells in the infarcted pig myocardium – complicated by myocardial tumor formation

H. Katus, A. Seckinger, A. Hansen, 2009, Scandinavian cardiovascular journal : SCJ.

prognostic relevance of the expression of its receptor The role of IGF-1 as a major growth factor for myeloma cell lines and the

T. Rème, M. Jourdan, J. Rossi, 2009 .

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

D. Hose, H. Goldschmidt, A. Jauch, 2020, Leukemia.

Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry.

D. Hose, W. Haefeli, A. Seckinger, 2014, Journal of chromatography. A.

JunB is a key regulator of multiple myeloma bone marrow angiogenesis

E. Wagner, D. Hose, H. Goldschmidt, 2021, Leukemia.

Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood.

W. Ansorge, C. Schwager, A. Ho, 2005, Experimental hematology.

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance

G. Requirand, M. Jourdan, J. Moreaux, 2022, Frontiers in Immunology.

RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma

B. Klein, J. Moreaux, D. Hose, 2017, Leukemia.

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

E. Wagner, D. Hose, H. Goldschmidt, 2017, Leukemia.

Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis

D. Hose, H. Goldschmidt, A. Jauch, 2017, Haematologica.

A Niche-Dependent Myeloid Transcriptome Signature Defines Dormant Myeloma Cells.

I. Amit, K. Vandyke, D. Hose, 2019, Blood.

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation

D. Hose, H. Goldschmidt, A. Jauch, 2017, Haematologica.

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Kinome expression profiling to target new therapeutic avenues in multiple myeloma

M. Jourdan, J. Moreaux, D. Hose, 2019, Haematologica.

The heterogeneity of human mesenchymal stem cell preparations--evidence from simultaneous analysis of proteomes and transcriptomes.

A. Ho, A. Seckinger, W. Kuschinsky, 2006, Experimental hematology.

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation

D. Hose, H. Goldschmidt, A. Jauch, 2010, Haematologica.

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma

T. Rème, B. Klein, J. Moreaux, 2014, Oncotarget.

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

G. Requirand, J. Moreaux, D. Hose, 2018, Clinical Epigenetics.

Pacemaker cell characteristics of differentiated and HCN4-transduced human mesenchymal stem cells.

A. Draguhn, C. Bruehl, D. Hose, 2019, Life Science.

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

D. Hose, H. Goldschmidt, A. Jauch, 2020, Leukemia.

Processus and recessus adhaerentes: giant adherens cell junction systems connect and attract human mesenchymal stem cells

W. Peitsch, H. Spring, A. Ho, 2007, Cell and Tissue Research.

[Allogenic transplantation of human mesenchymal stem cells for tissue engineering purposes: an in vitro study].

P. Kasten, A. Seckinger, N. Südkamp, 2004, Der Orthopade.

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

D. Hose, H. Goldschmidt, A. Jauch, 2015, Haematologica.

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial

D. Hose, H. Goldschmidt, A. Jauch, 2021, Cancers.

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

D. Hose, H. Goldschmidt, A. Jauch, 2021, Leukemia.

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2021, Blood Cancer Journal.

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2021, Blood cancer journal.

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2015, Leukemia.

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

D. Hose, H. Goldschmidt, A. Jauch, 2013 .

The Value of Anti-angiogenics in Multiple Myeloma Therapy

D. Hose, H. Goldschmidt, A. Seckinger, 2019, Tumor Angiogenesis.

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis

G. Lenz, D. Hose, H. Goldschmidt, 2021, Frontiers in Oncology.

Regulation of integrin and growth factor signaling in biomaterials for osteodifferentiation

E. A. Cavalcanti-Adam, J. Spatz, A. Seckinger, 2015, Beilstein journal of organic chemistry.

Antigen-mediated regulation in monoclonal gammopathies and myeloma.

D. Hose, B. Barlogie, N. Munshi, 2018, JCI insight.

Addition of Cyclophosphamide to Pomalidomide and Dexamethasone in Case of Suboptimal Response to Pomalidomide and Dexamethasone Alone in Relapsed and/or Refractory Multiple Myeloma: Results of the GMMG-Perspective Trial

D. Hose, H. Goldschmidt, A. Jauch, 2017 .

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Bart Barlogie, Hartmut Goldschmidt, Dirk Hose, 2009, Blood.

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

D. Hose, T. Phan, J. Pettitt, 2017, Blood.

Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics

D. Hose, H. Goldschmidt, O. Stegle, 2021, Nature Communications.

Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.

D. Hose, M. Peppelenbosch, D. Chesik, 2010, Experimental cell research.

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic range albuminuria.

D. Hose, H. Goldschmidt, A. Jauch, 2020, Blood.

molecule-6 cells through carcinoembryonic antigen-related cell adhesion Tumor cells in multiple myeloma patients inhibit myeloma-reactive

T. Rème, J. Rossi, B. Klein, 2013 .

Atrial‐Radiofrequency Catheter Ablation Mediated Targeting of Mesenchymal Stromal Cells

A. Ho, H. Katus, A. Seckinger, 2007, Stem cells.

Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment.

T. Rème, B. Klein, D. Hose, 2011, Experimental hematology.

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.

D. Hose, H. Goldschmidt, A. Jauch, 2016, Blood.

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.

D. Hose, H. Goldschmidt, A. Jauch, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.

B. Klein, D. Hose, A. Seckinger, 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma

B. Klein, J. Moreaux, D. Hose, 2016, British Journal of Cancer.

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14).

D. Hose, H. Goldschmidt, A. Jauch, 2011, Blood.

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2022, Blood Cancer Journal.

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

D. Hose, H. Goldschmidt, A. Jauch, 2020, Leukemia.

Hyaluronan Hydrogels Delivering BMP-6 for Local Targeting of Malignant Plasma Cells and Osteogenic Differentiation of Mesenchymal Stromal Cells

D. Hose, E. A. Cavalcanti-Adam, A. Seckinger, 2019, Acta biomaterialia.

Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone

D. Hose, H. Goldschmidt, A. Jauch, 2011, Cancer.

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.

Axel Benner, Thomas Hielscher, Bart Barlogie, 2008, Blood.

Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma

D. Hose, H. Goldschmidt, A. Ho, 2018, Cytometry. Part B, Clinical cytometry.

Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up

D. Hose, H. Goldschmidt, A. Jauch, 2021, British journal of haematology.

The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.

T. Rème, B. Klein, J. Moreaux, 2011, Srpski arhiv za celokupno lekarstvo.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

D. Hose, H. Goldschmidt, A. Jauch, 2018, Blood advances.

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2016, Haematologica.

Assays of osteogenic differentiation by cultured human mesenchymal stem cells.

A. Seckinger, U. Krause, C. Gregory, 2011, Methods in molecular biology.

Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stage

V. Pantesco, M. Jourdan, B. Klein, 2016, Cell cycle.

Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2016, American journal of hematology.

Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial

D. Hose, H. Goldschmidt, A. Jauch, 2017 .

Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions.

A. Seckinger, J. Burhenne, Dirk Theile, 2017, Oncology letters.

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma

D. Hose, F. Prósper, J. Miguel, 2015 .

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

D. Hose, H. Goldschmidt, A. Jauch, 2019, Blood Cancer Journal.

Resemblance-Ranking Peptide Library to Screen for Binders to Antibodies on a Peptidomic Scale

D. Hose, A. Seckinger, R. Popov, 2022, International journal of molecular sciences.

Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters

D. Hose, W. Haefeli, A. Seckinger, 2015, Cancer Chemotherapy and Pharmacology.

A niche

I. Amit, K. Vandyke, D. Hose, 2004 .

The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells

B. Klein, J. Moreaux, D. Hose, 2015, Haematologica.

Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines

A. Seckinger, J. Burhenne, S. Dettmer, 2016, Naunyn-Schmiedeberg's Archives of Pharmacology.

Fetal calf sera can distort cell-based luminescent proteasome assays through heat-resistant chymotrypsin-like activity.

A. Seckinger, J. Burhenne, S. Dettmer, 2015, Analytical Biochemistry.

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells

D. Hose, H. Goldschmidt, G. Morgan, 2015, BMC Medical Genomics.

A tissue-based approach to selection of reference genes for quantitative real-time PCR in a sheep osteoporosis model

D. Hose, A. Seckinger, A. Rösen‐Wolff, 2017, BMC Genomics.

707 A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers

D. Hose, G. Curigliano, A. Seckinger, 2022, Regular and Young Investigator Award Abstracts.

Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Is Downregulated in Multiple Myeloma with Consequneces for Myeloma Cell Growth and Bone Disease

B. Klein, D. Hose, A. Seckinger, 2012 .

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

T. Rème, J. Rossi, B. Klein, 2011, Haematologica.

Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.

T. Rème, J. Rossi, B. Klein, 2012 .

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

G. Requirand, J. Moreaux, D. Hose, 2018, Clinical Epigenetics.

Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers

D. Hose, A. Seckinger, L. Shang, 2023, Journal of Hematology & Oncology.

Assays of osteogenic differentiation by cultured human mesenchymal stem cells.

A. Seckinger, U. Krause, C. Gregory, 2011, Methods in molecular biology.

High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders

Martin Schorb, U. Hegenbart, A. Seckinger, 2023, Leukemia.

Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation

A. Jauch, A. Seckinger, U. Bertsch, 2024, JCO precision oncology.